Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
出版年份 2021 全文链接
标题
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP
作者
关键词
-
出版物
JOURNAL OF MEDICINAL CHEMISTRY
Volume 64, Issue 11, Pages 7839-7852
出版商
American Chemical Society (ACS)
发表日期
2021-05-27
DOI
10.1021/acs.jmedchem.1c00649
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC)
- (2020) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of selective degraders of EGFRL858R/T790M mutant
- (2020) Xin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide
- (2020) Kailun He et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and Synthesis of a Trifunctional Molecular System “Programmed” to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells
- (2020) Julie Schmitt et al. JOURNAL OF MEDICINAL CHEMISTRY
- An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development
- (2020) Sunita Shankar et al. Nature Communications
- Poly(ADP-ribose)-dependent chromatin unfolding facilitates the association of DNA-binding proteins with DNA at sites of damage
- (2019) Rebecca Smith et al. NUCLEIC ACIDS RESEARCH
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- Insights into the biogenesis, function, and regulation of ADP-ribosylation
- (2018) Michael S Cohen et al. Nature Chemical Biology
- Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 (BRCA2) Mutation
- (2018) Chong Du et al. ACS Nano
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
- (2017) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Lung cancer: current therapies and new targeted treatments
- (2017) Fred R Hirsch et al. LANCET
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Survival of pancreatic cancer cells lacking KRAS function
- (2017) Mandar Deepak Muzumdar et al. Nature Communications
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
- (2017) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Polypharmacology: Challenges and Opportunities in Drug Discovery
- (2014) Andrew Anighoro et al. JOURNAL OF MEDICINAL CHEMISTRY
- EGFR-Activating Mutations Correlate with a Fanconi Anemia-like Cellular Phenotype That Includes PARP Inhibitor Sensitivity
- (2013) H. N. Pfaffle et al. CANCER RESEARCH
- Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1
- (2013) Teresa Di Desidero et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dual targeting strategies with bispecific antibodies
- (2012) Roland Kontermann mAbs
- Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
- (2012) S Yoshikawa et al. ONCOGENE
- Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
- (2010) J. J. Wright CLINICAL CANCER RESEARCH
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- (2010) Federico Cappuzzo et al. LANCET ONCOLOGY
- Protein-binding assays in biological liquids using microscale thermophoresis
- (2010) Christoph J. Wienken et al. Nature Communications
- Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
- (2009) J. Veeken et al. CURRENT CANCER DRUG TARGETS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started